Michael Avraam, global product manager at ChargePoint Technology discusses the evolution of containment strategies, specifically within the role of containment verification and monitoring technology.
Fuelled by growth in the biopharma sector and the oncological and immune-suppressant fields, the pharmaceutical manufacturing industry is seeing a surge in demand for high potency active pharmaceutical ingredients (HPAPIs). This is leading many manufacturers to consider increasingly innovative containment strategies to meet these high potency handling requirements.